Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study BioSpacePemvidutide showed a "highly statistically significant" treatment effect in patients with alcohol use disorder.Metabolic & GLP-1Read full story pharminent July 28, 2026 (Last updated: July 30, 2026) BioSpace Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Metabolic & GLP-1 Read full story Post navigation Previous: GSK to quit Stevenage for new R&D site in CambridgeNext: GSK Unveils Three-Year Restructuring to Fund Late-Stage R&D Ahead of Patent Cliff Related Stories Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026 Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026 Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026
